Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Amortization of Deferred Charges of $912000.0 for Q2 2026, up 24.25% year-over-year from $734000.0 in Q2 2025, and up 8.06% quarter-over-quarter from $844000.0 in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Amortization of Deferred Charges for 8 consecutive years, with $912000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Amortization of Deferred Charges rose 24.25% year-over-year to $912000.0; the TTM figure through Jun 2026 stood at $3.3 million (up 26.13% YoY), while the FY2025 annual figure was $3.0 million, up 37.5% from the prior year.
- Amortization of Deferred Charges climbed to $912000.0 in Q2 2026 per PHAT's latest filing, from $844000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $912000.0 in Q2 2026 and bottomed at $273000.0 in Q2 2023.
- Historically, Amortization of Deferred Charges has averaged $608277.8 across 5 years, with a median of $565000.0 in 2022.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 76.4% — and 2024, when it jumped 83.15%.
- Phathom Pharmaceuticals' Amortization of Deferred Charges stood at $497000.0 in 2022, then advanced by 13.88% to $566000.0 in 2023, then climbed by 11.13% to $629000.0 in 2024, then climbed by 28.62% to $809000.0 in 2025, then rose by 12.73% to $912000.0 in 2026.
- Business Quant data shows PHAT's Amortization of Deferred Charges at $912000.0 in Q2 2026, $844000.0 in Q1 2026, and $809000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 912,000.00 |
| Mar 31, 2026 | 844,000.00 |
| Dec 31, 2025 | 809,000.00 |
| Sep 30, 2025 | 775,000.00 |
| Jun 30, 2025 | 734,000.00 |
| Mar 31, 2025 | 696,000.00 |
| Dec 31, 2024 | 629,000.00 |
| Sep 30, 2024 | 589,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 474,000.00 |
| Dec 31, 2023 | 566,000.00 |
| Sep 30, 2023 | 542,000.00 |
| Jun 30, 2023 | 273,000.00 |
| Mar 31, 2023 | 496,000.00 |
| Dec 31, 2022 | 497,000.00 |
| Sep 30, 2022 | 564,000.00 |
| Jun 30, 2022 | 531,000.00 |
| Mar 31, 2022 | 518,000.00 |
| Dec 31, 2021 | 507,000.00 |
| Sep 30, 2021 | 2.39 Mn |